Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
ApexOnco Front Page
Recent articles
The companies press on with vilastobart and IMPT-314... up to a point.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
